Plexxikon Inc.

Jack Lin

Prabha N Ibrahim

Wayne Spevak

Chao Zhang

Guoxian Wu

Ying Zhang

Jiazhong Zhang

Dean R Artis

Todd Ewing

Songyuan Shi

Marika Nespi

Katrina Chan

Phuongly Pham

John Buell

Hanna Cho

Weiru Wang

Michael V Milburn

Jeffrey Yung Wu

Clarence R Hurt

Heike I Krupka

James Arnold

Jason Walters

Shenghua Shi

Rebecca Zuckerman

Byunghun Lee

Ken Dong

Jeffrey Wu

Ryan Bremer

Aaron Edward Albers

Gideon Bollag

Zuojun Guo

Hannah Powers

Garson Tsang

Aaron Albers

Provided herein are intermediates and processes useful for facile synthesis of compounds of Formula 2: wherein Ris C(O)R; Ris alkyl optionally substituted with 1-5 halogens; G is phenyl or a 5-6 membered heteroaryl optionally substituted with 1-2 R; and each Ris independently C-Calkyl, CN, C-Calkyl-CN, 3-6 membered cycloalkyl, or 4-6 membered heterocycloalkyl.

Synthesis of heterocyclic compounds

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid were prepared and characterized in the solid state:  Also provided are processes of manufacture and methods of using the forms of Compound I.

Crystalline forms of a compound that inhibits bromodomain

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R, R, R, each R, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R, R, Q, Q, and Q, are described in this disclosure, compositions thereof, and methods and uses thereof.

Provided herein are intermediates and processes useful for facile synthesis of compounds of formula (I): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Q, Pand Pare as defined in this disclosure.

Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z, Z, and Zare as described herein, compositions thereof, and uses thereof.

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

Kinase modulation, and indications therefor

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, wherein the compounds are of Formula (I): Methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases are also described.

Growing community of inventors

Hercules, CA, United States of America

Jack Lin